The first animal studies showing that GLP-1 potentially had effects on the CV system was published in 2002, and the first study to show cardioprotection was in 2008 (102, 211), but it was not until the LEADER cardiovascular outcomes trial (CVOT) with liraglutide, published in 2016, that a reduction in CV risk with a GLP-1RA was documented (100)
You can find what tier a drug is on by checking your formulary or drug list
For instance, a small proportion of people have genetically low b12 values, while they do not have a deficiency
Mechanism of Action Understanding the mechanisms of these drugs explains their effectiveness
Advances in radiotherapy and immunity in hepatocellular carcinoma
Duration: Use Glutimax-1200 Injection as prescribed by your healthcare provider for the desired treatment duration